Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

Inclusion Criteria: * Adult subjects, ages 18-65 * Chronic HCV infection, defined as having documented HCV infection (antibody or RNA positivity) at least 6 months prior to Baseline (Day 1) with HCV viremia at screening * Screening Knodell necroinflammatory score \>= 3 based on liver biopsy evaluation (as determined by local pathologist) conducted anytime during the 45-day screening period * ALT \> the upper limit of the normal range (ULN) but \< 10 X ULN at the screening visit * Previously failed pegylated interferon-based HCV therapy in combination with ribavirin therapy, or is unable to tolerate or has contraindications to receiving interferon or ribavirin therapy * BMI between 19 and 36 kg/m2 (inclusive) * Creatinine clearance \>= 70 mL/min * absolute neutrophil count \>= 1000/mm3 * Hemoglobin \> 10 g/dL * Have no clinical or laboratory evidence of hepatic decompensation Exclusion Criteria: * Decompensated liver disease * Child-Pugh grade B or C cirrhosis * Evidence of hepatocellular carcinoma * Positive urine drug screen for cocaine or amphetamines * Infection with HCV genotype 3 * Co-infection with hepatitis B virus or human immunodeficiency virus * Pancreatitis * Recent significant infection or symptoms of infection * Autoimmune disorders * Any history of seizure * Is a public transportation operator (pilot of airplane or ship; air traffic controller; bus, train or subway driver) or operates heavy construction machinery * Transplantation * History of malignancy * Current excessive alcohol ingestion, averaging \> 3 drinks/day for females and \> 4 drinks/day for males * History of or current binge drinking